PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$147.32

Daily low

$144.44

Price at open

$146.18

52 Week High

$148.00

52 Week Low

$50.48

Market cap

9.4B

Dividend yield

0.00%

Volume

321,083

Avg. volume

590,055

P/E ratio

-81.04

Protagonist Therapeutics News